Because recent clinical trials that have targeted the classical inflammation pathways with, for example, minocycline [3] and uric acid [4], have failed to show efficacy, we speculated that the regulation of TLR4 signals by enhancing RANK signaling using rRANKL might be a novel strategy to treat ischemic stroke [1]. This evidence concerns the gene TNFRSF11A and ischemic stroke.